Avalyn Pharma (NASDAQ:AVLN) Stock Price Up 6.4% – What’s Next?

Avalyn Pharma Inc. (NASDAQ:AVLN) shares traded up 6.4% during mid-day trading on Wednesday. The company traded as high as $28.87 and last traded at $28.84. 160,187 shares were traded during trading, a decline of 48% from the average daily volume of 310,942 shares. The stock had previously closed at $27.10.

Analyst Upgrades and Downgrades

A number of research firms have commented on AVLN. Raymond James Financial assumed coverage on shares of Avalyn Pharma in a research report on Friday. They set an “outperform” rating and a $60.00 target price on the stock. Morgan Stanley lifted their price objective on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Weiss Ratings started coverage on Avalyn Pharma in a research report on Thursday, August 13th. They set a “sell (d+)” rating on the stock. Finally, Wall Street Zen lowered Avalyn Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Avalyn Pharma Trading Down 3.8%

The stock has a 50-day moving average of $33.49. The company has a market capitalization of $1.22 billion and a P/E ratio of -1.20. The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04.

Avalyn Pharma (NASDAQ:AVLN) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.05. As a group, analysts predict that Avalyn Pharma Inc. will post -3.81 EPS for the current year.

Hedge Funds Weigh In On Avalyn Pharma

Institutional investors have recently bought and sold shares of the business. Montanova Capital LLC purchased a new position in shares of Avalyn Pharma during the second quarter worth $82,402,000. Braidwell LP purchased a new position in shares of Avalyn Pharma in the 2nd quarter valued at about $26,382,000. State Street Corp acquired a new position in shares of Avalyn Pharma during the 2nd quarter worth approximately $10,501,000. Finally, Bank of New York Mellon Corp purchased a new position in Avalyn Pharma during the second quarter valued at $1,321,000.

Avalyn Pharma Company Profile

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company’s primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company’s development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.